Abstract

<div>Abstract<p><b>Purpose:</b> New therapeutic approaches are needed for patients with thyroid cancer refractory to radioiodine treatment. An inhibitor of bromodomain and extraterminal domain (BET) proteins, JQ1, shows potent antitumor effects in hematological cancers and solid tumors. To evaluate whether JQ1 is effective against thyroid cancer, we examined antitumor efficacy of JQ1 using the <i>Thrb<sup>PV/PV</sup>Kras<sup>G12D</sup></i> mouse, a model of anaplastic thyroid cancer.</p><p><b>Experimental Design:</b> We treated <i>Thrb<sup>PV/PV</sup>Kras<sup>G12D</sup></i> mice with vehicle or JQ1 at a dose of 50 mg/kg body weight/day starting at the age of 8 weeks for a 10-week period and monitored thyroid tumor progression.</p><p><b>Results:</b> JQ1 markedly inhibited thyroid tumor growth and prolonged survival of these mice. Global differential gene expression analysis showed that JQ1 suppressed the <i>cMyc</i> (hereafter referred to as <i>Myc</i>) transcription program by inhibiting mRNA expression of <i>Myc, ccnd1,</i> and other related genes. JQ1-suppressed <i>Myc</i> expression was accompanied by chromatin remodeling as evidenced by increased expression of histones and hexamethylene bis-acetamide inducible 1, a suppressor of RNA polymerase II transcription elongation. Analyses showed that JQ1 decreased MYC abundance in thyroid tumors and attenuated the cyclin D1–CDK4–Rb–E2F3 signaling to decrease tumor growth. Further analysis indicated that JQ1 inhibited the recruitment of BDR4 to the promoter complex of the <i>Myc</i> and <i>Ccnd1</i> genes in rat thyroid follicular PCCL3 cells, resulting in decreased MYC expression at the mRNA and protein levels to inhibit tumor cell proliferation.</p><p><b>Conclusions:</b> These preclinical findings suggest that BET inhibitors may be an effective agent to reduce thyroid tumor burden for the treatment of refractory thyroid cancer. <i>Clin Cancer Res; 23(2); 430–40. ©2016 AACR</i>.</p></div>

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call